Celecoxib for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
Obsessive-Compulsive Disorder+1 More
Celecoxib - Drug
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will help researchers understand if anti-inflammatory drugs can be effective in treating OCD when used in addition to traditional medications.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Week 8

TSPO Volume of Distribution assessed by PET imaging with [11C]ER-176
Week 8
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel
Yale-Brown Obsessive Compulsive Scale

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Obsessive-Compulsive Disorder

Side Effects for

Initial Dose Celecoxib 400 mg
5%Beta 2 microglobulin increased
3%Blood bilirubin increased
3%Beta-N-acetyl-D-glucosaminidase increased
1%Post procedural haemorrhage
1%Hypoaesthesia facial
1%Blood urine present
1%Urobilin urine present
1%Blood phosphorus decreased
1%Blood creatine phosphokinase increased
1%White blood cell count increased
This histogram enumerates side effects from a completed 2010 Phase 2 trial (NCT01062113) in the Initial Dose Celecoxib 400 mg ARM group. Side effects include: Beta 2 microglobulin increased with 5%, Blood bilirubin increased with 3%, Beta-N-acetyl-D-glucosaminidase increased with 3%, Eczema with 2%, Somnolence with 1%.

Trial Design

1 Treatment Group

Celecoxib Treatment
1 of 1
Experimental Treatment

21 Total Participants · 1 Treatment Group

Primary Treatment: Celecoxib · No Placebo Group · Phase 2

Celecoxib Treatment
Experimental Group · 1 Intervention: Celecoxib · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 8

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor
455 Previous Clinical Trials
148,554 Total Patients Enrolled
23 Trials studying Obsessive-Compulsive Disorder
891 Patients Enrolled for Obsessive-Compulsive Disorder
Jeffrey Miller, M.D.Principal Investigator - New York State Psychiatric Institute
New York Presbyterian Hospital-Columbia Presbyterian Center, New York State Psychiatric Institute
Yale University School Of Medicine (Medical School)
Ny And Presby Hospital (Residency)
1 Previous Clinical Trials
25 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have the capacity to give informed consent.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
New York State Psychiatric Institute100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%